BRTX

BioRestorative Therapies Inc

BRTX.US biorestorative.com
2.67
-0.09 (-3.26%)
USD · NASDAQ
52-week range
0.14
3.23
Trading at 82% of the 52-week range
Market Cap
3.69M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.38
Div. Yield
N/A
% Institutions
13.90%
% Insiders
9.56%

1 Year

-91.7%

3 Year

-91.8%

10 Year

-100.0%
Description

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Company Information

Company Name
BioRestorative Therapies Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US0906556065
CIK: 0001505497
CUSIP: 090655606
Currency: USD
Full Time Employees: 13
Phone: 631 760 8100
Fiscal Year End: December
IPO Date: Jul 27, 2007
Description:

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Address:

40 Marcus Drive, Melville, NY, United States, 11747

People

Directors & Officers

Name Title Year Born
Mr. Mika Grasso Interim CEO & Director 1998
Ms. Anna Skowron CFO & Treasurer 1987
Ms. Crystal Romano Head of Global Commercial Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 08, 2024 Francisco Silva N/A Purchase 1.71K $1.16 $1.98K
Feb 09, 2024 Dale Broadrick N/A Purchase 86.04K $1.32 $113.57K
Feb 07, 2024 Dale Broadrick N/A Purchase 36.37K $1.38 $50.20K
Dec 01, 2023 Dale Broadrick N/A Sale 250.00 $1.88 $470.00
Nov 27, 2023 Dale Broadrick N/A Sale 278.00 $1.89 $525.42
Sep 15, 2023 Lance Alstodt N/A Purchase 2.20K $1.70 $3.74K
Sep 14, 2023 Dale Broadrick N/A Purchase 10.00K $1.54 $15.40K
Sep 13, 2023 Lance Alstodt N/A Purchase 800.00 $1.53 $1.22K
Sep 07, 2023 Dale Broadrick N/A Purchase 1.00K $1.81 $1.81K
Sep 06, 2023 Lance Alstodt N/A Purchase 2.89K $1.96 $5.66K
Aug 31, 2023 Francisco Silva N/A Purchase 4.95K $2.22 $11.00K
Jul 28, 2023 Dale Broadrick N/A Purchase 500.00 $2.89 $1.45K
Jul 27, 2023 Dale Broadrick N/A Purchase 1.00K $2.80 $2.80K
Jul 25, 2023 Lance Alstodt N/A Purchase 4.20K $2.44 $10.25K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Citadel Advisors Llc 238.61K Mar 31, 2026 0.94% $0.00 717.20%
Geode Capital Management, LLC 223.08K Mar 31, 2026 0.88% $0.00 285.60%
UBS Group AG 99.83K Mar 31, 2026 0.39% $0.00 0.00%
Wealth Alliance, LLC 40.00K Jun 30, 2026 0.16% $0.00 0.00%
Vanguard Fiduciary Trust Co 39.45K Mar 31, 2026 0.15% $0.00 0.00%
State Street Corp 32.46K Mar 31, 2026 0.13% $0.00 0.00%
Keystone Financial Group Inc 28.60K Jun 30, 2026 0.11% $0.00 0.00%
Advisor Group Holdings, Inc. 2.00K Mar 31, 2026 0.01% $0.00 0.00%
Tower Research Capital LLC 1.46K Mar 31, 2026 0.01% $0.00 32.19%
SBI Securities Co Ltd 199.00 Mar 31, 2026 0.00% $0.00 67.23%
TD Waterhouse Canada Inc 3.00 Mar 31, 2026 0.00% $0.00 0.00%
DRW Securities, LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Napier Financial, LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
TWO SIGMA SECURITIES, LLC 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Bank of America Corp 0.00 Mar 31, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Extended Market Index 127.22K 0.03% ▲ 0.00% Jul 31, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 38.48K 0.01% ▲ 196.50% Jul 31, 2026
3 NT Ext Equity Mkt Index Fund - NL 21.58K 0.00% ▲ 0.00% Jun 30, 2026
4 NT Ext Equity Mkt Idx Fd - DC - NL - T2 15.65K 0.00% ▲ 0.00% Jun 30, 2026
5 Fidelity Total Market Index 13.41K 0.00% ▲ 0.00% Jul 31, 2026
6 Fidelity Series Total Market Index 8.56K 0.00% ▲ 0.00% Jul 31, 2026
7 Spartan Total Market Index Pool A1 3.23K 0.00% ▲ 0.00% Jul 31, 2026
8 Northern Trust Extended Eq Market Idx 2.43K 0.00% ▲ 0.00% Jun 30, 2026
9 NT Ext Equity Mkt Index Fund - Lending 2.43K 0.00% ▲ 0.00% Jun 30, 2026
10 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 959.00 0.00% ▲ 0.74% Mar 31, 2026

Financial Highlights

Market Cap: $3.69M
EBITDA: $-14.01M
PEG Ratio: $0.00
Book Value: $2.38
Earnings/Share: $-21.20
Profit Margin: 0.00%
Operating Margin: -14,612.57%
ROA (TTM): -118.81%
ROE (TTM): -241.14%
Revenue (TTM): $357.87K
Revenue/Share (TTM): $0.63
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -7.30%

Valuation Metrics

Enterprise Value: $-9.40M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 1.38M
Shares Float: 1.21M
% Insiders: 9.56%
% Institutions: 13.90%
Short % Float: 0.15%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$359.70K
Cost of Goods Sold
adjust
$-23.84K
Gross Profit
subtotal
$335.86K
SG&A
adjust
$-5.89M
R&D
adjust
$-10.09M
Operating Income
subtotal
$-15.65M
Other / Non-Operating Items
adjust
$1.41M
Net Income
subtotal
$-14.24M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BRTX.US!